David A. Siegel A Ikido Pharma Inc. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	N/A	-1,500 Reduced 7.61%	18,200 $69,000
Q3 2023 Nov 14, 2023	SELL	N/A	-900 Reduced 4.37%	19,700 $74,000
Q2 2023 Aug 14, 2023	SELL	N/A	-27,600 Reduced 57.26%	20,600 $78,000
Q1 2023 May 15, 2023	SELL	$3.46 - $4.07 $88,230 - $103,785	-25,500 Reduced 34.6%	48,200 $183,000
Q4 2022 Feb 14, 2023	SELL	$3.07 - $7.21 $39,910 - $93,730	-13,000 Reduced 14.99%	73,700 $241,000
Q3 2022 Nov 14, 2022	BUY	$5.6 - $7.03 $419,014 - $526,012	74,824 Added 630.04%	86,700 $593,000
Q2 2022 Aug 15, 2022	BUY	$4.59 - $7.99 $54,510 - $94,889	11,876 New	11,876 $70,000

461K

Ticker AIKI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,485,100
Market Cap $20.8M
Description
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small mo...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.